A virus‐derived microRNA targets immune response genes during SARS‐CoV‐2 infection

Meetali Singh(Centre National de la Recherche Scientifique), Maxime Chazal(Centre National de la Recherche Scientifique), Piergiuseppe Quarato(Centre National de la Recherche Scientifique), Loan Bourdon(Centre National de la Recherche Scientifique), Christophe Malabat(Institut Pasteur), Thomas Vallet(Centre National de la Recherche Scientifique), Marco Vignuzzi(Centre National de la Recherche Scientifique), Sylvie van der Werf(Centre National de la Recherche Scientifique), Sylvie Behillil(Centre National de la Recherche Scientifique), Flora Donati(Centre National de la Recherche Scientifique), Nathalie Sauvonnet(Institut Pasteur), Giulia Nigro(Inserm), Maryline Bourgine(Institut Pasteur), Nolwenn Jouvenet(Centre National de la Recherche Scientifique), Germano Cecere(Centre National de la Recherche Scientifique)
EMBO Reports
December 16, 2021
Cited by 60Open Access
Full Text

Abstract

SARS-CoV-2 infection results in impaired interferon response in patients with severe COVID-19. However, how SARS-CoV-2 interferes with host immune responses is incompletely understood. Here, we sequence small RNAs from SARS-CoV-2-infected human cells and identify a microRNA (miRNA) derived from a recently evolved region of the viral genome. We show that the virus-derived miRNA produces two miRNA isoforms in infected cells by the enzyme Dicer, which are loaded into Argonaute proteins. Moreover, the predominant miRNA isoform targets the 3'UTR of interferon-stimulated genes and represses their expression in a miRNA-like fashion. Finally, the two viral miRNA isoforms were detected in nasopharyngeal swabs from COVID-19 patients. We propose that SARS-CoV-2 can potentially employ a virus-derived miRNA to hijack the host miRNA machinery, which could help to evade the interferon-mediated immune response.


Related Papers